In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
university of oklahoma
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF hosted its semiannual meeting on Thursday.
OMRF, Stephenson Cancer Center begin tests of experimental compound
At this moment, you probably think of yourself as an I. As in, “I’m going to the grocery store to get some bread.” Or, “I’m running a slight fever.” Maybe even, “I’m so excited to read this new issue of Findings!” But what if you’re using the wrong pronoun? What if, despite your conscious perception, […]